On April 26, 2021 Biond Biologics Ltd. ("Biond" or the "Company"), a private clinical-stage biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, reported that the first patient has been dosed in the first-in-human, phase 1 clinical trial of BND-22 (SAR444881), an Ig-Like Transcript 2 (ILT2) receptor blocking antibody (Press release, Biond Biologics, APR 26, 2021, View Source [SID1234578511]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first patient was administered BND-22 at the Oncology Research Unit of the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, one of the six US and Israel trial sites planned to initially participate in the phase 1, open-label, dose escalation study exploring the safety, tolerability, pharmacokinetics (PK), anti-tumor activity, and exploratory biomarkers for BND-22 activity in patients with select advanced solid tumors.
"BND-22 represents a novel approach to cancer immunotherapy targeting both adaptive and innate immune cells," said Ravit Geva, M.D., Research Unit Head and Deputy Director, Division of Oncology at the Tel Aviv Sourasky Medical Center, and a clinical investigator in the trial. "There continues to be an urgent need to develop new treatments for patients with cancers refractory to standard of care therapy. BND-22 has demonstrated compelling preclinical activity, and we look forward to further investigate the potential of ILT2 blockade in this Phase 1 study."
"The entry of BND-22 into the clinic is a significant milestone for Biond as it represents the achievement of an important aspect of the company’s vision to progress our novel medicines into clinical evaluation while using our drug discovery, development, and translation capabilities," said Tehila Ben Moshe, Ph.D., Co-Founder and Chief Executive Officer of Biond. "BND-22, a multi-cell checkpoint inhibitor, was studied extensively by our scientific team for several years and was found to have the potential to improve upon current treatment paradigms, either as a monotherapy or in combination. Based on in-depth translational studies of real-world patient samples we have designed the Phase 1 trial to focus on patient populations we believe are most likely to respond to ILT2 blockade. We look forward to the results of the BND-22-001 trial as we strive to improve the treatment of cancer patients with dire needs for new therapies."
Biond announced on January 12th, 2021 an exclusive worldwide license agreement with Sanofi, for the development and commercialization of BND-22. Under the terms of the agreement, Biond will lead the first-in-human, phase 1 study of BND-22, evaluating its safety and tolerability as a single agent and in combination with approved cancer therapeutics as well as exploring the association between BND-22 anti-tumor activity and select tumor and blood-based biomarkers; Sanofi will assume clinical development and commercialization responsibilities thereafter.
About BND-22
BND-22 is a humanized IgG4, antagonist antibody targeting the ILT2 receptor in development for the treatment of solid tumors. ILT2, a member of the ILT family of immuno-modulating receptors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds major histocompatibility complex (MHC) class I molecules including HLA-G, an immunosuppressive protein expressed by multiple tumor types.
BND-22 has been shown in preclinical studies to have a broad anti-tumor effect by targeting ILT2-mediated "do not eat me" signals in macrophages and by activating NK and CD8+ lymphocytes. The program is supported by a comprehensive biomarker strategy designed to guide patient enrollment in advanced clinical trials.
BND-22-001 is the first-in-human clinical trial of BND-22. It is a Phase 1/2 multicenter, open-label, dose escalation and expansion study enrolling advanced cancer patients with solid tumor types known to express HLA-G. Following dose escalation and determination of BND-22′ recommended Phase 2 dose, the study design allows for the expansion of patient cohorts to evaluate the anti-tumor activity of BND-22 in specific tumor types. BND-22-001 is planned to be expanded to also evaluate the safety and anti-tumor activity of BND-22 in combination with other therapies. For more information about the trial, including participating medical centers, please visit View Source (Trial Identifier: NCT04717375).